Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terence Friedlander

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Annals of Translational Medicine|February 5, 2020
A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancerDaniel Hyuck-Min Kwon, Terence Friedlander
Oncology and Therapy|April 7, 2021
Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case ReportClaire Greene, Brigid Barlesi, Sigrid Tarroza-David, et al.
Clinical Genitourinary Cancer|January 9, 2022
Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case SeriesTanya Jindal, Jonathan Chou, Terence Friedlander, et al.
Frontiers in Oncology|July 25, 2022
Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature ReviewDame Idossa, Terence Friedlander, Channing J Paller, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|February 6, 2025
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial CarcinomaKevin K Zarrabi, Abhiraj Saxena, Kent W Mouw, et al.
JAMA Oncology|October 20, 2017
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate CancerNima Almassi, Chad Reichard, Jianbo Li, et al.
The Oncologist|March 19, 2017
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate CancerXiao X Wei, Andrew C Hsieh, Won Kim, et al.
Transplantation Direct|December 16, 2020
Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management StrategiesDominic Amara, Steven A Wisel, Hillary J Braun, et al.
JCO Oncology Practice|December 21, 2021
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate CancerDaniel H Kwon, Sneha Karthikeyan, Alison Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Annals of Translational Medicine|February 5, 2020
A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancerDaniel Hyuck-Min Kwon, Terence Friedlander
Oncology and Therapy|April 7, 2021
Improved Control of Tyrosine Kinase Inhibitor-Induced Diarrhea with a Novel Chloride Channel Modulator: A Case ReportClaire Greene, Brigid Barlesi, Sigrid Tarroza-David, et al.
Clinical Genitourinary Cancer|January 9, 2022
Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case SeriesTanya Jindal, Jonathan Chou, Terence Friedlander, et al.
Frontiers in Oncology|July 25, 2022
Case Report: Clinical Characteristics and Outcomes of HIV Positive Patients With Metastatic Prostate Cancer Treated With Immunotherapy: A Case Series and Literature ReviewDame Idossa, Terence Friedlander, Channing J Paller, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|February 6, 2025
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial CarcinomaKevin K Zarrabi, Abhiraj Saxena, Kent W Mouw, et al.
JAMA Oncology|October 20, 2017
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate CancerNima Almassi, Chad Reichard, Jianbo Li, et al.
The Oncologist|March 19, 2017
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate CancerXiao X Wei, Andrew C Hsieh, Won Kim, et al.
Transplantation Direct|December 16, 2020
Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management StrategiesDominic Amara, Steven A Wisel, Hillary J Braun, et al.
JCO Oncology Practice|December 21, 2021
Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate CancerDaniel H Kwon, Sneha Karthikeyan, Alison Chang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate CancerIvan de Kouchkovsky, Arpit Rao, Benedito A Carneiro, et al.
Pageof 4